æ±äº¬å·¥æ¥å€§åŠ(æ±å·¥å€§)ãç¥å¥å·çç«ç£æ¥æè¡ç·åç ç©¶æ(KISTEC)ãå¥è¯çç«å»ç§å€§åŠ(å¥è¯å»å€§)ã®3è ã¯3æ4æ¥ãæ°åã³ãããŠã€ã«ã¹(SARS-CoV-2)ã«å¯ŸããŠé«ãäžæŽ»å广ã瀺ãè€åé žåç©ãéçºãããšçºè¡šããã
åææã¯ãæ±å·¥å€§ ç©è³ªçå·¥åŠé¢ ææç³»ã®äŒæ±ææå€§åŠé¢çãåã»ç£¯éšæå®åææãåã»æŸäžç¥¥ååææãåã»äžå³¶ç« ææãKISTEC ç ç©¶éçºéšã®ç ç°éŠç¢ä¹åžžå€ç ç©¶å¡ãåã»æ°žäºæŠåžžå€ç ç©¶å¡ãåã»ç³é»æãµããªãŒããŒãå¥è¯å»å€§ 埮çç©ææçåŠè¬åº§ã®éŽæšç±åžå€§åŠé¢çãåã»äžéç« ä»£å©æãåã»äžéç«äžåææãåã»ç¢éå¯¿äžææãã®å ±åç ç©¶ããŒã ã«ãããã®ã詳现ã¯ããªã©ã³ãã®ç§åŠèªã Materials Lettersãã«æ²èŒãããã
æ°åã³ãããŠã€ã«ã¹ææç(COVID-19)ã®äºé²ãæ¡å€§ã®æå¶ãå®çŸãããããæãŠã€ã«ã¹ææãæ±ããããŠãããæãŠã€ã«ã¹ææã«ã¯ææ©ç³»ãšç¡æ©ç³»ããããç¡æ©ç³»ã¯æŽå²ãæµ ããã®ã®ããã®åªãã广ãããã£ãŠããããšãããè¿å¹Žã¯ç ç©¶ãå¢å ããŠããŠãããšãããç¡æ©ç³»ã¯ãæ¯èŒçåºã枩床ç¯å²ã§ããŸããŸãªãŠã€ã«ã¹ã«å¯ŸããŠå¹æãçºæ®ãããã®ãå€ãããšãããŠã€ã«ã¹ãèæ§ãç²åŸãã«ãããªã©ã®çç±ãããæãŠã€ã«ã¹ææãšããŠæåŸ ãããŠããã
ç¡æ©ç³»ã®ä»£è¡šãšããŠã¯ãé ãªã©ã®éå±ã€ãªã³ãé«ãæãŠã€ã«ã¹æŽ»æ§ã瀺ãããšãç¥ãããŠããããã ãé ã¯ãé žåã«ããæãŠã€ã«ã¹æŽ»æ§ã®äœäžãæãããšãåé¡ãšãªã£ãŠããããŸãäºé žåãã¿ã³ãªã©ã®å è§ŠåªææãæãŠã€ã«ã¹ææã ããå ç §å°ãå¿ èŠãšãããããææã§ã¯æŽ»æ§ãçºçŸããªãããã®ã»ããç³ç°(é žåã«ã«ã·ãŠã )ãé žåäºéã«ãæãŠã€ã«ã¹æŽ»æ§ãããããšã¯ç¥ãããŠããããåå£ã®ã¢ã«ã«ãªåãæŽ»æ§ã®çµæå£åãæŽ»æ§ã®äœããªã©ã®èª²é¡ãæ±ããŠããã
ç¡æ©ç³»ã§æ±ºãæãšãªãæãŠã€ã«ã¹ææã¯ãããŸã§ã®ãšãããªãã仿ããææãããããæ±ããŠãã課é¡ãå æããæ°ããªæãŠã€ã«ã¹ææã®éçºãæ±ããããŠããã®ã§ããã
2019å¹Žãæ±å·¥å€§ã®äžå³¶ææãçããç ç©¶ããŒã ã¯ãèªå·±æ¥æ°Žæ§ãå ±åãããŠããé žåã©ã³ã¿ã³ãšãæè掻æ§ãå ±åãããŠããé žåã¢ãªããã³ãçµã¿åãããè€åé žåç©ã§ãããLa2Mo2O9ã(LMO)ã®æèã»æãŠã€ã«ã¹æŽ»æ§ã®åæãè¡ã£ãã
ãã®çµæãLMOã¯ææã«ãããŠçްè(å€§è žèãšé»è²ãããŠçè)ãšãŠã€ã«ã¹(ãã¯ããªãªãã¡ãŒãžQβããã³åΊ6)ã«å¯Ÿããé«ãæèã»æãŠã€ã«ã¹æŽ»æ§ãçºçŸããç¹åŸŽçãªé žåç©ã§ããããšãè§£æããããŸãLMOã¯ãã€ã³ãã«ãšã³ã¶ãŠã€ã«ã¹ãææããMDCK现è(ã€ãã®è èããåé¢ãããäžç®ã®ç ç©¶çšå¹é€çްè)ã«å¯Ÿããæ¯æ§ããªãããšã倿ã
ç¡æ©ç³»ã®æãŠã€ã«ã¹ææãšããŠæåŸ ãããããå®ã¯èŠæãšããŠãããã®ããã£ããLMOã¯å€§è žèãé»è²ãããŠçèããããŠãŠã€ã«ã¹Qβã«å¯ŸããæŽ»æ§ãšæ¯èŒããŠããšã³ãããŒãåãŠã€ã«ã¹ã§ããΊ6ã«å¯ŸããæŽ»æ§ãäœãã£ãã®ã ã
ãŠã€ã«ã¹ã¯ãšã³ãããŒãæ§é ãæã£ãŠãããããªããã§ã倧ãã2çš®é¡ã«åããããšãå¯èœã ãã©ã®ãŠã€ã«ã¹ããã²ãã ãåãå²ãã¿ã³ãã¯è³ªã®æ®»ã§ãããã«ãã·ããããããäžéšã®ãŠã€ã«ã¹ã§ã¯ãã®ã«ãã·ããèŠãããã«ããŠèç¶ã®æ§é ã§ãããšã³ãããŒãããããèå¿ãªããšã¯ãSARS-CoV-2ããã®ãšã³ãããŒãåã®ã²ãšã€ã ãšããããšãã€ãŸãLMOãSARS-CoV-2ã«å¯ŸããæãŠã€ã«ã¹ææãšããããã«ã¯ããã®æŽ»æ§ãé«ããããšã倧ããªèª²é¡ã ã£ãã®ã§ããã
ãã®èª²é¡ãæ€èšããéçšã«ãããŠãäžå³¶ææãã¯LMOã®ã©ã³ã¿ã³ã®äžéšãåãåžåé¡ã§ããã»ãªãŠã ã«çœ®ãæããããšã§ãΊ6ã«å¯ŸããæŽ»æ§ãé«ãŸãããšãçºèŠãããã§äžå³¶ææãã¯ä»åãLMOã®ã©ã³ã¿ã³ããã¹ãŠã»ãªãŠã ã«çœ®æããè€åé žåç©ã®åæã詊ã¿ãã®ã§ããã
ã©ã³ã¿ã³ãšã¯ç°ãªããã»ãªãŠã ã¯è€æ°ã®äŸ¡æ°ãæã€ããšãããã»ãªãŠã ãšã¢ãªããã³ãå«ãè€åé žåç©ã§ã¯äœè£œæ¡ä»¶ã®ããããªéãã§ããŸããŸãªçµæ¶çžãåºçŸããŠããŸããããåå±€ç²(åäžçµæ¶çžãããªãç²æ«)ãåŸããã«ããããšãé£ç¹ã§ããã
ããã§äžå³¶ææãã¯åææ¡ä»¶ãåºçºææã倿Žããªãããåå±€ç²ã®äœè£œå®éšãç¹°ãè¿ããŠé©åãªæ¡ä»¶ã®æ¢çŽ¢ãç¶ããããããŠã髿ž©é«å§ã®ç±æ°Žã®ååšäžã§è¡ãååç©åææ³ã§ãããæ°Žç±åææ³ããçšããããšã§ããã¢ãªããã³é žã»ãªãŠã (γ-Ce2Mo3O13:CMO)ãã®åçžç²ã®åæã«æåããã®ã§ããã
CMOã«ã€ããŠãKISTECã®ç³é»ãµããªãŒããŒããQβãšÎŠ6ã«å¯ŸããæãŠã€ã«ã¹æŽ»æ§è©äŸ¡ããã³ã¿ã³ãã¯è³ªå€æ§è©Šéšã宿œãããŸãå¥è¯å»å€§ã®ç¢éææããæ°åã³ãããŠã€ã«ã¹ã«å¯ŸããæãŠã€ã«ã¹æŽ»æ§è©äŸ¡ã宿œããã®çµæãΊ6ã ãã§ãªããåããšã³ãããŒãåã®SARS-CoV-2ã«å¯ŸããŠãé«ãæãŠã€ã«ã¹æŽ»æ§ãçºçŸããããšãèŠåºãããã®ã§ãããããã«LMOãšåæ§ã«ãMDCK现èã«å¯Ÿããæ¯æ§ãå°ãªãããšã確èªãããã
-

ææå¥ã®SARS-CoV-2ã®çåéã®å€åãã°ã©ãã®çžŠè»žã¯SARS-CoV-2ã®çåéã察æ°ã§è¡šç€ºãããŠãããæž¬å®ã¯ISOèŠå®ã®ãã£ã«ã å¯çæ³ãçšãããããã¬ã©ã¹äžã®ãŠã€ã«ã¹éã¯å€åããªãããLMOã«Ceã10ïŒ æ·»å ããLCMOã¯ãŠã€ã«ã¹æ¿åºŠã6æéã§çŽ1.5æ¡(çŽ1/30)ã«äœäžãããCMOç²æ«ã§ã¯4æéã§ãŠã€ã«ã¹æ¿åºŠã¯4æ¡ä»¥äž(1/1äžä»¥äžã«)äœäžããããšãèŠãŠåããããã®æŽ»æ§ã¯MoO3ãããé«ããCeãšçµã¿åãããããšã®å¹æã確èªã§ãã (åºæ:å ±åãã¬ã¹ãªãªãŒã¹PDF)
-

äžèšã®å®éšã«ãããŠã4æéã®æç¹ã§ã®(a)ã¬ã©ã¹ãšã(b)CMOã®éãã宿䞻现èãæ£åžžã«çããŠãããšéè²ã«æè²ããããããŠã€ã«ã¹ãååšãããšå®¿äž»çްèãæ»æ» ãæè²ãããªããããéæãªãã©ãŒã¯ã圢æããããã¬ã©ã¹äžã§ã¯ãŠã€ã«ã¹ãååšãã倧éã®ãã©ãŒã¯ãååšããããCMOã«ã¯ãã©ãŒã¯ããŸã£ãããªãããŠã€ã«ã¹ãæ€åºéçãŸã§äžæŽ»åããŠããããšã確èªã§ãã (åºæ:å ±åãã¬ã¹ãªãªãŒã¹PDF)
CMOã®æãŠã€ã«ã¹æ©æ§ã¯å®å šã«ææ¡ãããããã§ã¯ãªãããæº¶åºããã¢ãªããã³é žã€ãªã³ãšãšãã«ã埮éã®ã»ãªãŠã ã€ãªã³ãé¢äžããŠããããšã瀺åããããšããã
å»çåŸäºè ã®ããã®ã¯ã¯ãã³æ¥çš®ã2æããæ¥æ¬ã§ãå§ãŸãã4æã«ã¯é«éœ¢è åãã«ãã¹ã¿ãŒããããããã£ãšäžã®äžä»£ãŸã§è¡ãæž¡ãã«ã¯ãŸã ãã°ããæéããããããšãäºæ³ãããŠããããã®ããã«ã¯ã¯ãã³ãæ®åãããŸã§ã¯ãŸã æéããããããããã®éãçµæžæŽ»åãç€ŸäŒæŽ»åãç¶æããããã«ã¯ãææã®äºé²ãæ¡å€§æå¶ã«é¢ããæè¡ããæ²»çæ³ã®ç¢ºç«ãã¯ã¯ãã³ã®éçºãšåæ§ã«éèŠã ã
ä»åã®ç ç©¶ææã¯ãã¯ã¯ãã³é Œã¿ã®SARS-CoV-2察çããã®ã²ãŒã ãã§ã³ãžãšãªãæ°ããªéãéãå¯èœæ§ããããšããããããŠãããã ãã§ã¯ãªããè¿å¹Žãæ¥æ¬ã«ãããŠé »çºããŠããå€§èŠæš¡èªç¶çœå®³ã«ãã被çœå°ã§ã®è¡çç°å¢ç¢ºä¿ã®é¢ã«ãããŠããæå¹ãªæè¡ãšãªãå¯èœæ§ããããšããŠããã
LMOã«ã€ããŠã¯ãã§ã«è©Šäœãã¹ã¿ãŒããããŠããããŸãä»åéçºããCMOã«ã€ããŠãéããã«è©Šäœãéå§ããæ©æ¥ãªå®çšåãç®æããšããŠããã